AbbVie Acquires Gilgamesh Pharmaceuticals' Psychedelic Candidate Bretisilocin

Oct 20, 2025
AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals’ investigational compound bretisilocin, a next-generation psychedelic currently in Phase 2 trials for major depressive disorder.

AbbVie has completed the acquisition of Gilgamesh Pharmaceuticals' investigational compound bretisilocin, announced in a press release. The compound is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for moderate-to-severe major depressive disorder.

Bretisilocin is designed as a next-generation psychedelic compound intended to address challenges seen with traditional psychedelics. AbbVie stated that recent clinical data suggest the compound has potential as a treatment for patients with major depressive disorder.

With the acquisition finalized, AbbVie plans to accelerate bretisilocin’s development as part of its psychiatry pipeline expansion.

We hope you enjoyed this article

Free newsletter

AI Funding Brief

Guide
AI app builders

AI app builders

Tools that turn a description into a working web or mobile app, and the platforms companies use to build internal tools with AI

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.